pubmed.ncbi.nlm.nih.gov

Change in Prolactin Levels in Pediatric Patients Given Antipsychotics for Schizophrenia and Schizophrenia Spectrum Disorders: A Network Meta-Analysis - PubMed

  • ️Mon Jan 01 2018

Review

. 2018 Apr 1:2018:1543034.

doi: 10.1155/2018/1543034. eCollection 2018.

Affiliations

Review

Change in Prolactin Levels in Pediatric Patients Given Antipsychotics for Schizophrenia and Schizophrenia Spectrum Disorders: A Network Meta-Analysis

Chakrapani Balijepalli et al. Schizophr Res Treatment. 2018.

Abstract

Background: Treatment of schizophrenia with first- and second-generation antipsychotics has been associated with elevated prolactin levels, which may increase the risk for prolactin-related adverse events.

Methods: Randomized controlled trials (RCTs) included in a recent systematic review were considered for this analysis. A Bayesian network meta-analysis was used to compare changes in prolactin levels in pediatric patients diagnosed with schizophrenia or schizophrenia spectrum disorders treated with second-generation antipsychotics (SGAs).

Results: Five RCTs, including 989 patients combined, have evaluated the changes in prolactin for pediatric patients after 6 weeks of treatment with risperidone, quetiapine, aripiprazole, olanzapine, and paliperidone. In the overall study population, treatment with risperidone was associated with the highest increase in mean prolactin levels compared to other SGAs. Patients treated with risperidone 4-6 mg/day were found to experience the greatest increases (55.06 ng/ml [95% CrI: 40.53-69.58]) in prolactin levels, followed by risperidone 1-3 mg/day, paliperidone 3-6 mg/day, and paliperidone 6-12 mg/day.

Conclusions: This study shows that there are differences in SGAs ability to cause hyperprolactinemia. Further, there is clear evidence of safety concerns with risperidone and paliperidone treatment in adolescent schizophrenia patients.

Registration: PROSPERO CRD42014009506.

PubMed Disclaimer

Figures

Figure 1
Figure 1

Complete evidence network of the trials included in the analyses that reported change in prolactin levels.

Figure 2
Figure 2

The evidence network of the trials that reported change in prolactin levels by sex.

Similar articles

Cited by

References

    1. van Os J., Kapur S. Schizophrenia. The Lancet. 2009;374(9690):635–645. doi: 10.1016/S0140-6736(09)60995-8. - DOI - PubMed
    1. Kumperscak H. G. Childhood and Adolescent Schizophrenia and Other Early-Onset Psychoses, Psychiatric Disorders - Trends and Developments. InTech; 2011.
    1. Martin A. Lewis's Child and Adolescent Psychiatry: A Comprehensive Textbook. 4th. London, UK: Lippincott, Wiliams & Wilkins; 2007.
    1. Halperin Rabinovich I., Camara Gomez R., Garcia Mouriz M., Ollero Garcia-Agullo D. Grupo de Trabajo de Neuroendocrinologia de la S [Clinical guidelines for diagnosis and treatment of prolactinoma and hyperprolactinemia] Endocrinología y Nutrición. 2013;60(6):308–319. - PubMed
    1. Majumdar A., Mangal N. S. Hyperprolactinemia. Journal of Human Reproductive Sciences. 2013;6(3):168–175. doi: 10.4103/0974-1208.121400. - DOI - PMC - PubMed

Publication types

LinkOut - more resources